Loading...
RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.
Sort By: Relevancy | Date | Type
Displaying items 13-24 of 137
» View ky3.com items only
    May 12, 2013 |Story| Los Angeles Times

  1. Lieuwe Westra wins Amgen Tour's first stage under brutal heat

    ESCONDIDO, Calif. — Lieuwe Westra, red-faced and shaking, was the winner of Sunday's first stage at the Amgen Tour of California, on a day when temperatures on the route were recorded as high as 105 degrees.
    ESCONDIDO, Calif. — Lieuwe Westra, red-faced and shaking, was the winner of Sunday's first stage at the Amgen Tour of California, on a day when temperatures on the route were recorded as high as 105 degrees. James Stemper, of the 5-hour Energy/...

    Tags: Tour of California, Lieuwe Westra, Peter Sagan

    2. May 12, 2013 |Story| Los Angeles Times

  2. Bill would regulate 'biosimilar' drugs

    SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs.
    SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs. At stake is a...

    Tags: Viral Diseases and Infections, Chemical Industry, Genentech Inc., Health and Medical Professionals, Jerry Hill

    3. May 6, 2013 |Story| Los Angeles Times

  3. Amgen at a glance

    The company: Amgen Inc. Headquarters: Thousand Oaks Ticker: AMGN Employees: 18,000 Leadership: Robert A. Bradway, chief executive since May 2012 2012 revenue: $17.3 billion 2012 net income: $4.3 billion Stock price: $106.48 at Friday's close...
    4. May 6, 2013 |Story| Los Angeles Times

  4. Amgen aims to restock its medicine cabinet

    Amgen Inc. is a biotechnology company that develops medicines used in the treatment of cancer, kidney disease, arthritis, bone disease and other serious illnesses.
    Amgen Inc. is a biotechnology company that develops medicines used in the treatment of cancer, kidney disease, arthritis, bone disease and other serious illnesses. The Thousand Oaks company's top-selling products include arthritis medication Enbrel,...

    Tags: Kidney Disease, Chemical Industry, Technology, Biotechnology Industry, Science and Technology

    5. May 5, 2013 |Story| Los Angeles Times

  5. A wife's Alzheimer's, a husband's obsession

    Ken Chiate is a born problem-solver, and in the summer of 1961, when he was on break from college, his problem was a head-turning blond named Jeannette.
    Ken Chiate is a born problem-solver, and in the summer of 1961, when he was on break from college, his problem was a head-turning blond named Jeannette. He was head lifeguard at a public pool in Phoenix, where his father owned a liquor store. She worked...

    Tags: Alzheimer's Disease, Health and Medical Professionals, Crime, Law and Justice, Rentals, Parkinson's Disease

    6. Apr 29, 2013 |Story| Aberdeen News

  6. LETTER: ALEC too far right for these groups

     The American Legislative Exchange Council (ALEC) is a group promoting far-right legislation. Its tax exempt status is currently challenged, as its sole purpose is to formulate legislation promoting extremely conservative points of view and helping the...

    Tags: Environmental Issues, Deere and Company, CVS Corp., Reckitt Benckiser, McDonald's

    7. Apr 26, 2013 |Story| Los Angeles Times

  7. L.A. jury finds three guilty in $1.5-million Medicare fraud scheme

    A federal jury in Los Angeles found an Anaheim physician and two others guilty this week for their roles in a $1.5-million Medicare fraud scheme involving power wheelchairs. At trial, federal prosecutors said that Godwin Onyeabor, 49, an officer at...

    Tags: FBI, Crime, Law and Justice, Drugs and Medicines, Justice System, Government Health Care

    8. Apr 24, 2013 |Story| Los Angeles Times

  8. Shares of biotech giant Amgen slide on disappointing sales

    Shares of biotech giant Amgen Inc. slumped Wednesday as investors reacted to weaker-than-expected first-quarter sales.
    Shares of biotech giant Amgen Inc. slumped Wednesday as investors reacted to weaker-than-expected first-quarter sales. Shares of the Thousand Oaks company dropped $6.41, or nearly 6%, to $106.35 in trading Wednesday. The company's stock had posted...

    Tags: Enbrel (drug), Rheumatoid Arthritis

    9. Apr 11, 2013 |Story| Los Angeles Times

  9. Letters: Medicare and Amgen

    Re "Remove Medicare's straitjacket," Opinion, March 29 Art Kellerman misunderstands why Congress delayed inclusion of oral-only drugs in the Medicare payment bundle for dialysis services. It wasn't to give Amgen and other drug makers a major windfall;...

    Tags: U.S. Congress, Health and Medical Professionals, Government Health Care, Oral and Maxillofacial Surgeons, Medicare

    10. Apr 5, 2013 |Story| Hartford Courant

  10. Pfizer Partners With Nanotechnology Firm

    McClatchy-Tribune News Service
    Pfizer Inc. said Wednesday that a new collaboration with Massachusetts-based BIND Therapeutics could eventually lead to drug work at company laboratories in Groton. New York-based Pfizer confirmed a deal Wednesday that would pay BIND up to $200 million...

    Tags: Chemical Industry, Technology, Health Treatments, Science and Technology, Pharmaceuticals

    11. Mar 29, 2013 |Story| Los Angeles Times

  11. Remove Medicare's straitjacket

    Now that the budget "sequester" is in effect, Congress is shifting its attention to entitlement reform. There's simply no way to achieve long-term reductions in federal spending without touching the big health programs, particularly Medicare. Although raising the age of Medicare eligibility from 65 to 67 appears off the table, at least for now, the budget plan that Rep. Paul D. Ryan (R-Wis.) is proposing would shift a greater share of the program's growing costs to beneficiaries in the years to come.
    Now that the budget "sequester" is in effect, Congress is shifting its attention to entitlement reform. There's simply no way to achieve long-term reductions in federal spending without touching the big health programs, particularly Medicare. Although...

    Tags: Chemical Industry, Genentech Inc., Private Health Care, Food and Drug Administration, Science and Technology

    12. Mar 17, 2013 |Story| Los Angeles Times

  12. Battle over 'biosimilars'

    One of the most promising frontiers in healthcare is biologic medicines — complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies what amounts to a 12-year monopoly on the substances they developed. Now, supporters of biologics are pushing lawmakers in Sacramento and other state capitals to put new hurdles in the way of knock-off compounds, called "biosimilars."
    One of the most promising frontiers in healthcare is biologic medicines — complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies...

    Tags: Chemical Industry, Genentech Inc., Technology, Health and Medical Professionals, Jerry Hill

< Previous • 1  2  3 4 5 6 7 8 9 10 11-12 • Next >
Original site for Amgen Inc. topic gallery.
Loading...
 
 

Date:

Credit:

User-submitted

Tags:

Rate:
Sending...

E-mail this photo

Error: malformed email address(es)
Both "from" and "recipient" email fields are required.

Recipient E-mail Addresses

(up to 3, separated by commas) Send me a copy.

From:

e-mail | buy this photo | link to photo
Amgen Inc. Photos
Thousand Oaks-based biotechnology company Amgen Inc. ha...
(May 14, 2013)
6: Amgen Inc.
Some firms seek to make "biosimilar" drugs that would p...
(April 25, 2013)
Bill would regulate &#8216;biosimilar&#8217; drugs
, Rathmann was the Thousand Oaks firm's first chief exe...
(April 25, 2012)
George B. Rathmann
 » All 5 Amgen Inc. photos